← Browse by Condition
Medical Condition

lung adenocarcinoma

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for lung adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — lung adenocarcinoma Clinical Trials

How many clinical trials are currently recruiting for lung adenocarcinoma?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for lung adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for lung adenocarcinoma?
lung adenocarcinoma research spans Phase 1 (1 trial), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a lung adenocarcinoma clinical trial?
Eligibility criteria for lung adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Phase 3
1
Top Sponsors
Palo Alto Veterans Institute for Research 1 trial
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo 1 trial
Fu Jen Catholic University 1 trial
Sun Yat-sen University 1 trial
Second Life Therapeutics 1 trial

Recruiting Clinical Trials

NCT07219251
Recruiting
Engagement of Veterans With Lung Cancer
Enrollment
194 pts
Location
United States
Sponsor
Palo Alto Veterans Institute f...
View Trial →
NCT07633626
Recruiting
Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
Enrollment
24 pts
Location
Colombia
Sponsor
Centro de Tratamiento e Invest...
View Trial →
NCT07012759
Recruiting
Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients
Enrollment
100 pts
Location
Taiwan
Sponsor
Fu Jen Catholic University
View Trial →
NCT07481786 Phase 3
Recruiting
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
Enrollment
220 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT07341737 Phase 1, Phase 2
Recruiting
SL-28 for Advanced Solid Tumours
Enrollment
60 pts
Location
Australia
Sponsor
Second Life Therapeutics
View Trial →
NCT05517811
Recruiting
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
Enrollment
200 pts
Location
United States
Sponsor
University of Colorado, Denver
View Trial →

Related Conditions

lung cancer nsclc (2) lung cancer non small cell (2) esophageal cancer (2) liver cancer (2) colorectal cancer (2) lung carcinoma (1) lung cancer small cell (1) lung adenocarcinoma with bronchiolo alveolar feature (1) advanced alk ros1 positive nsclc (1) carcinoma non small cell lung nsclc (1) alk positive non small cell lung cancer nsclc (1) cognitive dysfunction (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology